Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 5/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835169 | 0.86 | ALDH1A1 (0.38) | KIF11IDO1RAPGEF4PDE2ATSHR | |
| SCHEMBL30581108 | 0.76 | RAPGEF4 (0.52) | KIF11IDO1RAPGEF4CES2TSHR | |
| SCHEMBL241686 | 0.74 | ALDH1A1 (0.42) | KIF11IDO1RAPGEF4PDE2ATSHR | |
| Hydrochloric Acid SCHEMBL20984299 | 0.74 | ALDH1A1 (0.42) | IDO1RAPGEF4CES2TSHRMAPK1 | |
| Bromide SCHEMBL20984676 | 0.74 | ALDH1A1 (0.38) | IDO1RAPGEF4CES2TSHRMAPK1 | |
| SCHEMBL10616863 | 0.74 | NOTUM (0.34) | IDO1RAPGEF4CES2TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL26131624 | 0.74 | RAPGEF4 (0.50) | KIF11IDO1RAPGEF4CES2PTPN5 | |
| SCHEMBL360584 | 0.74 | MAPT (0.44) | RAPGEF4CES2GAA | |
| Hydrochloric Acid SCHEMBL5745583 | 0.73 | ALDH1A1 (0.41) | IDO1RAPGEF4PDE2ATSHRGAA | |
| Bromide SCHEMBL20984180 | 0.72 | MAPT (0.42) | RAPGEF4CES2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7902232-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | ZOETIS SERVICES LLC | 2009-05-28 | — | — | US | disclosed |
| US-7514464-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1705989-B8 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-1705989-B1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7435753-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| EP-1901608-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006134466-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| EP-1705989-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| US-20060014802-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2006-01-19 | — | — | US | disclosed |
| US-20050148649-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2005-07-07 | — | — | US | disclosed |
| WO-2005060749-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | KIF11 3322/4885IDO1 1141/4885RAPGEF4 2167/4885 |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | KIF11 3322/4885IDO1 1141/4885RAPGEF4 2167/4885 |
| US-20050148649-A1 | Substituted arylpyrazoles | CYP3A4, CYP4B1, CYP1B1 | KIF11 1565/4885IDO1 420/4885RAPGEF4 1395/4885 |
| US-20060014802-A1 | Substituted arylpyrazoles | CYP4X1, ARG1, CYP2C9 | KIF11 3533/4885IDO1 901/4885RAPGEF4 2095/4885 |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A43, CYP3A4, CYP4X1 | KIF11 1564/4885IDO1 778/4885RAPGEF4 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.